BPC-157 site injection tips: what the science supports

What did @official.justin.bucki actually say?

In a short instructional video, the creator walked through how to inject BPC-157 intramuscularly into the bicep for a bicep strain. The main claim worth examining: "you don't actually have to spot inject it where the injury is." He said BPC-157 works systemically, so injecting into belly fat or the shoulder would deliver the same benefit as injecting near the injury site. He then demonstrated IM injection technique anyway, because the client wanted it in the muscle near the injury. He also briefly touched on aspiration, saying he personally skips it but showed it anyway.

So there are really two separate claims here: one about systemic versus local delivery, and one about injection technique. They deserve to be looked at separately, because the evidence behind them is very different.

Does the science back this up?

The systemic claim is where things get genuinely complicated. Most of the BPC-157 data comes from rodent studies using oral or intraperitoneal administration, not subcutaneous or intramuscular injection near an injury site. Sikiric et al. (2018, Current Pharmaceutical Design) documented healing effects across multiple tissue types in animal models regardless of administration route, which does suggest some systemic mechanism is at play. That is a real finding. But translating "works systemically in rats" into "site of injection in humans does not matter" is a bigger leap than the creator implies.

There are no published randomized controlled trials in humans comparing local versus remote injection of BPC-157 for musculoskeletal injuries. The peptide is not FDA-approved for any indication. The honest answer to "does it matter where you inject?" is: we genuinely do not know in humans. Saying it definitively does not matter overstates what the evidence supports.

What did they get wrong, and what did they get right?

Credit where it is due: the claim that BPC-157 does not require injection directly at the injury site is biologically plausible given animal data on systemic activity (Sikiric et al., 2018). Telling a client they do not have to inject into a painful, inflamed area is a reasonable harm-reduction position, not quackery.

But the creator presents this as settled fact. It is not. The statement "with BPC, you don't actually have to spot inject it where the injury is to get the results" implies equivalence between delivery routes that has never been demonstrated in a human clinical trial. That is misleading, even if the underlying biology is plausible.

On aspiration: current nursing and medical guidance from organizations like the CDC and WHO has moved away from routine aspiration for IM injections given the low vascular density of most IM sites. The creator's casual approach to this, saying "I don't do it," is actually consistent with current practice guidelines for standard IM sites. Whether the same applies to injecting into a bicep near an injury is a separate question he does not address.

What should you actually know?

BPC-157 is a research peptide. It is not approved by the FDA for any condition. The human evidence base for any BPC-157 injection protocol is essentially nonexistent at the clinical trial level. Animal models showing healing activity across tissue types are interesting and worth following, but they are not a clinical roadmap.

If you are considering peptide therapy for a musculoskeletal injury, a few things matter more than the injection site debate: the source and purity of your peptide, whether you are working with a licensed provider who can actually assess your injury, and whether you have ruled out structural damage that needs imaging or surgical evaluation. A bicep strain that warrants peptide therapy should already have a diagnosis.

Injecting into an already injured muscle based on a TikTok tutorial, even a technically competent one, carries real risks including infection, nerve injury, and improper dosing. This video is not a substitute for clinical oversight.